Chemexpress(688131) 证券之星·2025-03-27 16:47Group 1 - The core opinion of the internal control audit is that Shanghai Haoyuan Pharmaceutical Co., Ltd. maintained effective financial reporting internal controls as of December 31, 2024, in all material respects according to the relevant regulations [2][2][2] - The responsibility for establishing and implementing effective internal controls lies with the board of directors of Haoyuan Pharmaceutical, as per the guidelines and standards set forth [1][1][1] - The inherent limitations of internal controls mean that they may not prevent or detect misstatements, and changes in circumstances can lead to inadequacies in internal controls [1][1][1] Group 2 - The audit was conducted in accordance with the "Guidelines for Internal Control Audits" and relevant Chinese CPA standards [1][1][1] - The auditors are responsible for expressing an opinion on the effectiveness of internal controls based on the audit work performed and disclosing any significant deficiencies noted [1][1][1]